At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
GSK598809 +1 moredrug
Likely dose
GSK598809 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT and NRT for Smoking Cessation and Prevention of Very Early Relapse to Smoking
In Brief
A Phase 2 clinical trial evaluating GSK598809 and Placebo for Nicotine Dependence. Completed, enrolled 84 participants across 1 site.
Detailed Summary
The purpose of this research study is to find out if an investigational drug, GSK598809 can help people who have very recently quit smoking; the investigators want to find out if continuing to take GSK598809 over six weeks can help prevent smokers from relapsing. To relapse means you "fall back" into smoking again after quitting. The investigators also want to find out if GSK598809 is safe to take without causing too many side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionMay 2013
TodayJul 2026
First PostedAug 26, 2010
Enrollment StartAug 1, 2010
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.8 years ago
Interventions
GSK598809drug
Oral dose of 60 mg/day for a treatment period six weeks
Placebodrug
Placebo